Imperial College London
Alternate

Professor Toby Maher

Faculty of Medicine, National Heart & Lung Institute

Professor of Interstitial Lung Disease
 
 
 
//

Contact

 

+44 (0)20 7594 2151t.maher

 
 
//

Assistant

 

Ms Georgina Moss +44 (0)20 7594 2151

 
//

Location

 

364Sir Alexander Fleming BuildingSouth Kensington Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Kreuter:2023:rheumatology/keac325,
author = {Kreuter, M and Hoffmann-Vold, A-M and Matucci-Cerinic, M and Saketkoo, LA and Highland, KB and Wilson, H and Alves, M and Erhardt, E and Schoof, N and Maher, TM},
doi = {rheumatology/keac325},
journal = {Rheumatology},
pages = {S143--S153},
title = {Impact of lung function and baseline clinical characteristics on patient-reported outcome measures in systemic sclerosis-associated interstitial lung disease},
url = {http://dx.doi.org/10.1093/rheumatology/keac325},
volume = {62},
year = {2023}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - OBJECTIVE: The SENSCIS® trial demonstrated a significant reduction of lung function decline in patients with systemic sclerosis (SSc)-associated interstitial lung disease (SSc-ILD) treated with nintedanib, but no significant effect on health-related quality of life (HRQoL). To assess whether SSc/SSc-ILD severity and large changes in lung function correlate with HRQoL, a post-hoc analysis of SENSCIS®, aggregating treatment arms, was undertaken. METHODS: Patient-reported outcome (PRO) measures (St. George's Respiratory Questionnaire [SGRQ], Functional Assessment of Chronic Illness Therapy [FACIT]-Dyspnoea, and Health Assessment Questionnaire-Disability Index [HAQ-DI], incorporating the Scleroderma Health Assessment Questionnaire visual analogue scale [SHAQ VAS]) at baseline and week 52 were assessed for associations to SSc-ILD severity. RESULTS: At baseline and at week 52, forced vital capacity (FVC) <70% predicted was associated with worse PRO measure scores compared with FVC ≥70% predicted (week 52: SGRQ 45.1 vs 34.0 [p< 0.0001]; FACIT-Dyspnoea 48.9 vs 44.5 [p< 0.0001]; HAQ-DI 0.7 vs 0.6 [p< 0.0228]; SHAQ VAS breathing problems 3.6 vs 2.6 [p< 0.0001]). Patients with diffuse cutaneous SSc and other characteristics associated with SSc-ILD severity had worse PRO measure scores. Patients requiring oxygen or with >30% fibrosis on high-resolution computed tomography at baseline demonstrated worse PRO measure scores at week 52. After 1 year, patients with a major (>10%) improvement/worsening in FVC demonstrated corresponding improvement/worsening in SGRQ and other PRO measures, significant for the SGRQ symptom domain (p< 0.001). CONCLUSION: Severe SSc-ILD and major deteriorations in lung function have important impacts on HRQoL. Treatments that slow lung function decline and prevent severe SSc-ILD are important to preserve HRQoL. TRIAL REGISTRATION: clinicaltrials.gov, www.clinicaltrials.gov, NCT02597933.
AU  - Kreuter,M
AU  - Hoffmann-Vold,A-M
AU  - Matucci-Cerinic,M
AU  - Saketkoo,LA
AU  - Highland,KB
AU  - Wilson,H
AU  - Alves,M
AU  - Erhardt,E
AU  - Schoof,N
AU  - Maher,TM
DO  - rheumatology/keac325
EP  - 153
PY  - 2023///
SN  - 1462-0324
SP  - 143
TI  - Impact of lung function and baseline clinical characteristics on patient-reported outcome measures in systemic sclerosis-associated interstitial lung disease
T2  - Rheumatology
UR  - http://dx.doi.org/10.1093/rheumatology/keac325
UR  - https://www.ncbi.nlm.nih.gov/pubmed/35640959
UR  - http://hdl.handle.net/10044/1/97516
VL  - 62
ER  -
Download